| Prev Close | 0.00 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 1.89 / 6.37 |
Progenics Pharmaceuticals, Inc. (PGNX)
0.00
NASDAQ
| Exchange | NASDAQ |
| Div & Yield | N.A. (N.A) |
Latest News
These 2 Biotech Stocks Are Seeing Insider Buying Activity
We're focused on Progenics Pharmaceuticals and Aerie Pharmaceuticals.
Following These 2 Small-Caps Into Earnings
I'm looking forward to hearing from Progenics Pharmaceuticals and Builders FirstSource.
These 3 Biotech Stocks Are Moving Closer to Profitability
Here are updates on small biotech/biopharma names I have profiled before.
My Post-Earnings Assessment of 2 Biotech Stocks
Let's look at a couple of companies we have covered on these pages before.
3 Small Biotechs to Watch as Earnings Season Winds Down
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
My 2 Top Stock Picks for 2019
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
Here Are 3 Small-Cap Names for Biotech Investors to Consider
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
Here's a Handful of Ways to Navigate Biotech's Choppy Seas
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
My Options Strategy for These 2 Biotech Stocks
It's weeks like this that I'm glad I have some 'dry powder' to deploy.
Buy Struggling Progenics and Dynavax Here
Both biotech stocks are at or near 52-week lows, but don't deserve to be.
Seeking Bargains on Last Week's Selloff
These 5 stocks are a good value on this weakness.
Names to Watch Amid Biotech's Nascent Rally
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.
How I See Biotechs Now
I expect deal volume to have a substantial uptick before the end of 2018 rolls around.
3 Stocks to Consider Now
Two things usually occur right after earnings season winds down.
Strategies for 3 Biotechs Before FDA Action
Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.
ASCO's Big Winner: Loxo Oncology
Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.
4 Names to Watch Ahead of This Year's Key Cancer-Research Conference
These names are moving up or down in a big way ahead of releasing drug-trial results.
4 Names to Watch Ahead of Cancer Conference
American Society of Clinical Oncology will see presentations from dozens of companies.
4 Names to Buy in a Refreshed Biotech Space
After a strong week for the biotech sector, these names have potential catalysts to move shares.
Getting Ready for Biotech Earnings
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
Increasing My PGNX Exposure
Waiting for the market to open on this last day of the trading week. Looks like a slightly up opening based on futures right now. I think there is decent chance equities rally a bit here today and claw back some of yesterday's deep losses. Chinese '...
5 Stocks That Are Showing Signs of Reversing
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Watch These Biotechs and the FDA Calendar
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
3 Key Biotech Catalysts on the FDA Calendar
A roundup of biotech names with actions pending at the FDA in coming weeks.
Reversal Offers Chance in 2 Small Biotechs
I've added to my positions in these names on yesterday's intraday silliness.
3 Tiny Explosive Biotech Stocks for 2018
Sector M&A activity is likely to pick up next year benefiting the space.
4 Small-Caps on My Earnings Watch List
We are coming my favorite part of earnings season -- when these small-caps report.
Housing Stocks Will See Demand Boost
The housing market will continue to improve over the next few years due to pent up demand.